Synaptic dysfunction is a key early process in many neurodegenerative diseases, but how this ultimately leads to neuronal loss is not clear. In health, there is ongoing remodelling of synapses and spines in the adult brain: their elimination and formation are continual physiological processes fundamental to learning and memory. But in neurodegenerative disease, including prion disease, lost synapses are not replaced, and their loss is followed by neuronal death. These two processes are separately regulated, with mechanistic, spatial and temporal segregation of the respective death routines of synapses and cell bodies. Mice with prion disease can be cured at the stage of early synaptic dysfunction, when they have reversible impairments at neurophysiological, behavioural and morphological levels. Critically, reversing synaptic dysfunction at this stage of disease rescues neurons, preventing its otherwise inevitable progression to synapse loss and cell death. These findings call for a deeper analysis of the mechanisms underlying neurotoxicity at the synapse, and have important implications for the therapy of prion and other neurodegenerative disorders.
Introduction
Compromised synaptic function is thought to underlie the earliest symptoms in several neurodegenerative diseases, and loss of synapses, spines and dendrites precedes the loss of neuronal cell bodies. Synapses have an intrinsic potential to be strengthened and replaced, whereas neuronal loss is irreversible, making the early stages of disease a highly attractive target for treatment. The remodelling of synapses is fundamental to the maintenance of health of the adult brain. Activity-dependent structural changes in synaptic connectivity underlie many forms of experiencedependent plasticity, including learning and memory, the loss of which is central to many neurodegenerative disorders. Furthermore, synaptic connectivity between neurons is critical for their survival. A key approach is to couple investigation of synaptic dysfunction with analysis of the processes regulating synaptic regeneration, repair and plasticity that occur continuously in the adult brain.
Synaptic integrity requires the maintenance of contacts between (postsynaptic) spines, both persistent and transient, and (presynaptic) axonal boutons. Experience-dependent plasticity involves increasing both the synaptic strength (more spines per bouton) and number (new spines to existing boutons). Spine growth precedes synapse formation in the adult brain, and new synapses tend to be formed with existing Key words: behaviour, neurodegeneration, neurophysiology, prion protein (PrP), synaptic dysfunction. Abbreviations used: Aβ, amyloid β-peptide; AD, Alzheimer's disease; EPSP, excitatory postsynaptic potential; HD, Huntington's disease; LTP, long-term potentiation; PD, Parkinson's disease; PrP, prion protein; PrP C , cellular isoform of PrP; PrP Sc , disease-associated isoform of PrP; RNAi, RNA interference; wpi, weeks post-inoculation. 1 To whom correspondence should be addressed (email grm7@le.ac.uk).
boutons [1] , suggesting that the critical information is in the presynaptic neuron. Axonal size and branching pattern appear to be largely stable throughout life, but for some cells there is a high degree of plasticity of boutons, with rapid turnover, giving rise to the concept of cell-type-specific axonal plasticity [2] . This is likely to be essential for the remodelling of neuronal circuits at the presynaptic level.
Both pre-and post-synaptic structures are targeted in neurodegenerative disease and the effects on cognition may result from structural or functional changes at several levels, but where disease begins is unclear. How plasticity is affected in disease has also not been understood. Cognitive decline is strongly correlated with loss of presynaptic terminals in AD (Alzheimer's disease), independently of amyloid plaque load and neuronal loss [3] , and Aβ (amyloid β-peptide) oligomers are potent inhibitors of synaptic function and memory in mice in the absence of synaptic loss [4, 5] . In mouse models of AD, loss of spines in the amygdala and hippocampus are associated with cognitive deficits [6] ; and Aβ oligomer formation may drive the predominant elimination over formation of spines near Aβ plaques [7] . HD (Huntington's disease) and PD (Parkinson's disease) mouse models show similar phenomena [8] [9] [10] [11] . Mice experimentally infected with prions show changes in species-typical motivational behaviours long before emergence of motor signs [12] [13] [14] that correlate with early loss of presynaptic terminals in the dorsal hippocampus [15] , and in vivo imaging shows that persistent, but not transient, spines are lost in prion-infected animals, before neuronal loss [16] . Further, preventing neuronal apoptosis (but not synaptic dysfunction) stops cell death, but not the development of clinical disease in mice expressing a mutant form of PrP (prion protein) associated with inherited prion disease [17] .
Therefore defining the pathophysiological mechanisms underlying synaptic dysfunction and its progression to neurodegenerative disorders not only promises to increase our understanding of these, but also opens up new avenues for early diagnosis and, critically, for early treatment. Understanding these processes in the context of endogenous processes of plasticity may give further insights. Obstacles to progress in the field include the absence of a 'good' animal (invariably mouse) model for many of these diseases and a lack of reliable cognitive behavioural assays in mice, in particular, as readouts of synaptic function. Our recent work looking at early synaptic dysfunction in prion disease addresses both issues. In contrast with mouse models of AD, HD and PD (where human mutant proteins are expressed in mice with variable biochemical and pathological 'phenocopying' of the human diseases), mice infected with prions have prion disease. They replicate infectious mouse prions, develop classic prion pathology and show clinical signs of prion neurodegeneration. Thus studying these animals promises to give real insights into the pathological mechanisms of prion disorders. Using experimentally infected mice, we focused on the earliest stages of prion disease to try and understand the potential for rescue of both the function and survival of neurons in these disorders [18, 19] .
Prion synaptopathy: reversing early dysfunction rescues neurons in the long term
Central to prion pathogenesis is the conversion of a hostencoded PrP, PrP C (cellular isoform of PrP), into a partially protease-resistant isoform, PrP Sc (disease-associated isoform of PrP), which accumulates in the brain and is associated with infectivity. This process is self-propagating, with PrP Sc acting as a conformational template recruiting PrP C for further conversion. This conversion reaction is critical to the neurotoxicity of prion diseases as neither loss of PrP C function [20] [21] [22] 
nor deposition of PrP
Sc is sufficient to cause pathology.
We had previously established that prevention of formation of PrP Sc by knocking out PrP C in prion-infected mice during the course of disease prevented neuronal loss and progression to clinical disease. The animals were effectively clinically cured [23] . There were two key findings here. PrP knockout during the course of disease in prion-infected animals produced both long-term survival and neuroprotection, and the reversal, or recovery, of early spongiform change. Spongiform degeneration in prion disorders involves the formation of membrane-bound vacuoles within neurons and neuropils (predominantly within dendrites and intradendritic distensions), and dendritic spine loss co-localizes with vacuolar pathology in the hippocampus in mouse scrapie [24] . Spongiosis is thus a pre-degenerative change occurring in neurons that are not yet lost, but may represent an early morphological marker of functional impairment.
In our model, the first spongiform changes appeared approx. 8 weeks post-infection, 4 weeks before diagnostic motor symptoms would normally be detected. In mice with PrP knockout, reversal of spongiosis occurred soon after this. We therefore asked two questions: did this early spongiform change produce detectable functional synaptic deficits, and, if so, was its reversal reflected in functional synaptic recovery?
We used prion-infected transgenic mice with and without 'induced' PrP depletion. Tg37 mice express PrP from 'floxed' PrP sequences succumb to Rocky Mountain Laboratories (RML) prion infection ∼13 wpi (weeks post-inoculation). The earliest prion pathological changes appear by 8 wpi. In double transgenic NFH-Cre/tg37 mice, floxed PrP sequences are excised by Cre recombinase at approx. 9 weeks of age, resulting in neuronal PrP depletion at this time [22] . NFHCre/tg37 mice infected with prions at 1 week of age develop early hippocampal pathology in parallel with control tg37 mice, but spongiosis reverses soon after Cre-mediated PrP depletion approx. 8-9 wpi, and critically, the animals survive in the long term [23] .
As the focus for the pathological findings and their reversal was the hippocampus, we tested prion-infected animals in behavioural tasks known to depend on hippocampal integrity in vivo, and we measured synaptic transmission and plasticity in vitro. We found that, in parallel with the onset of spongiosis, mice developed behavioural and neurophysiological deficits. Further, in parallel with the reversal of spongiform change in PrP-depleted mice, the functional deficits recovered. We used simple behavioural tasks not affected by mouse strain or genetic background. Novel object recognition is a non-spatial learning task based on rodents' spontaneous preference for novelty and their ability to remember previously encountered objects [25] . Burrowing activity is a powerful indicator of brain function [26] in rodents, requiring a high degree of organization and executive function. It has a robust association with early prion pathology [12] [13] [14] and localizes to the dorsal hippocampus.
At 7 wpi, all prion-infected animals displayed normal novel object discrimination and burrowed actively (Figure 1) . However, at 8 wpi, all mice lost the ability to discriminate novel objects and stopped burrowing, coinciding with the appearance of early spongiform change [18] and with reduction of synaptic responses (Figure 1) . In prion-diseased tg37 mice, the impairment of memory and burrowing activity persisted throughout the course of infection and never recovered. In contrast, NFH-Cre/tg37 mice recovered novel object memory and burrowing behaviour very soon after neuronal PrP C depletion in parallel with reversal of spongiosis and with recovery in synaptic transmission (Figure 1 and see [18] ). Further, the functional recovery was sustained for all tasks up to 20+ wpi.
Specifically, synaptic responses and plasticity were tested in the stratum radiatum of the CA1 region of hippocampal slices taken from mice at specific time points after infection. At 8 wpi, both prion-infected tg37 and NFH-Cre/tg37 mice showed similar significant reductions in evoked EPSPs (excitatory postsynaptic potentials) at approx. 50% of the Figure 1 Neuronal depletion of PrP C allows recovery of burrowing behaviour and the ability to discriminate novel objects that are both lost in early prion infection in mice (A) Healthy rodents 'burrow' food pellets, carrying them out of a container and into their cage. (B) Early in prion infection, all mice burrowed equally. Burrowing then declined significantly in both tg37 and NFH-Cre/tg37 mice at 9 wpi and continued to decline in tg37 mice. In mice with Cre-mediated PrP depletion burrowing behaviour resumed by 10 wpi and remained normal up to 30 wpi. (C) Mice are allowed to explore two objects in an arena during the learning phase of the test; then, after a retention interval, they are exposed to a novel object (test phase). Time spent actively exploring the novel object compared with the familiar one is a measure of object recognition memory and is expressed as exploratory ratio.
(D) Prion-infected tg37 (white bars) and NFH-Cre/tg37 mice (black bars) showed normal object recognition memory at 7 wpi, with preferential exploration of the novel object. This was significantly impaired in all mice by 8 wpi, but recovered in mice with Cre-mediated PrP depletion at 9 wpi. Recovery was sustained up to 30 wpi. *P < 0.05; **P < 0.01; ***P < 0.001 (Student's t test; two-tailed). Open arrow indicates onset of earliest signs of scrapie in tg37 mice (ss). Closed arrow indicates onset of Cre-mediated PrP knockout.
values seen in both uninfected mice and in recovered NFHCre/tg37 animals ( Figure 2A ). Cre-mediated neuronal PrP depletion in NFH-Cre/tg37 mice resulted in rapid recovery of EPSPs to control levels, a recovery sustained in mice examined up to 18 wpi. In contrast, synaptic responses in the prion-infected tg37 mice continued to decline, and at 9 wpi, they were 22% of those of uninfected control mice. Action potentials in the presynaptic axons give rise to 'fibre volleys'; the amplitude of these was linearly related to the EPSP magnitude at each time point ( Figure 2C ), suggesting that the change in EPSP was directly due to a change in the presynaptic action potentials. Interestingly, when we measured LTP (long-term potentiation), a form of synaptic plasticity linked with some forms of learning and memory, we found no reduction in LTP in any of the prion-infected mice throughout the course of the experiment. Thus reduction in synaptic transmission in this model is not associated with changes in conventional measures of plasticity [18] , but may involve aberrant synaptic functions at several levels, including that of the presynaptic axon. Indeed, learning and memory have been associated with impaired synaptic responses and intact LTP in other rodent models [27] .
Other than spongiform change, we did not find other evidence for synapse loss or neuronal loss at this early stage of disease. Immunohistochemistry and semi-quantitative Western blotting for synaptophysin in our model did not reveal changes in the level of this presynaptic marker, suggesting that the functional changes detected precede quantifiable synapse loss here, in contrast with findings reported elsewhere, where burrowing impairment in prion disease correlates with presynaptic terminal loss in CA1 [12] .
The sequence of events that lead from synaptic dysfunction to synapse loss to neuronal cell body death in prion disease is not clear. As prion disease advances, dendrite loss occurs Figure 2 In prion-infected mice, synaptic responses are decreased but these recover when neuronal PrP C is depleted, whereas synaptic plasticity is preserved (A) Marked differences in field EPSP slope input-output curves between the experimental groups are shown. Means for the experimental groups in the GLM (General Linear Modelling) analysis reveal significantly smaller EPSPs in scrapie-infected tg37 mice (white bars) than in both NFH-Cre/tg37 mice (black bars) after PrP depletion at 9 wpi and uninfected control mice (grey bar). However, after Cre-mediated PrP depletion, synaptic responses return to control levels in NFH-Cre/tg37 mice at 9 wpi and are sustained at this level up to 18 wpi. P < 0.001, pairwise comparisons, using the Bonferroni correction for multiple comparisons; the dotted line represents mean EPSP value and broken lines represent 95% confidence intervals of the control group. (B) Representative sample traces for each group. The amplitude of response in uninfected control mice is shown at the top. This amplitude is reduced at 8 wpi in tg37 and NFH-Cre/tg37 mice and is further diminished in tg37 mice at 9 wpi. The response recovers in mice with PrP depletion at 9 wpi, which is sustained in mice up to 18 wpi. (C)
Deficits in synaptic responses correlate with reduction in the presynaptic axonal fibre volley: the relationship between EPSP slope and fibre volley amplitude is unaltered during scrapie infectivity (linear regression, solid line, R 2 = 0.97).
before neuronal loss [16] . Loss of dendrites may be secondary to presynaptic changes as well. Both mRNA and miRNA (microRNA) screens of prion-infected mouse brains show that both pre-and post-synaptic proteins are targets of altered gene regulation during prion disease [28] . Interestingly, just as behavioural deficits rapidly recovered, correcting within a week, loss of EPSP and fibre volleys were also rapidly reversible (also a week). Deficit and recovery cannot be due to neuronal loss, nor can they be due to regrowth of axons within this timeframe. But the regeneration of dendrites, neurites and synapses is possible within this period. It may be that the formation of new spines and synapses contributes to the reversibility of early prion disease, possibly ameliorating axonal dysfunction and strengthening synaptic transmission. This clearly needs addressing in future studies. Interestingly, using lentivirally mediated RNAi (RNA interference) of PrP, we recently confirmed that knocking down PrP production at the transcriptional level prevented, rather than rescued, the onset of cognitive deficits in control mice [19] . In contrast with mice with genomic PrP deletion, where deficit developed and then recovered, hippocampal injection of lentivirus expressing anti-PrP shRNAs (smallhairpin RNAs) at 8 wpi prevented their manifestation altogether, perhaps because post-transcriptional gene silencing is a more rapid or more tightly controlled process temporally. Interestingly, the RNAi-treated group also had very limited spongiosis. Treated mice also survived significantly longer than untreated mice. Analysis of this cohort revealed that the effect on survival depended on time of inoculation: the longest surviving animals were treated relatively earlier in the week; the shortest surviving animals were treated a few days later. Thus either earlier intervention is exerting its effects through interference with the kinetics of prion replication or it is acting at a critical period in neuronal death 'routines' or both [29, 30] .
A further mechanistic implication of this work is that synaptic dysfunction is independent of aggregated misfolded protein deposition. Thus both impairment and recovery in our model appeared to be independent of PrP Sc accumulation. Functional deficits appeared at 8 wpi, before extensive deposits of PrP Sc are apparent, and their recovery was independent of aggregated PrP Sc deposition, which continues to accumulate due to extraneuronal, predominantly astrocytic, replication. Thus, as for AD [4, [31] [32] [33] and other neurodegenerative disease models [9, 34, 35] , the results strongly support a transient, soluble, non-aggregating species, which is probably generated within neurons, causing synaptic dysfunction in prion disease.
These findings have opened new avenues in the prion field. To date, prion infection in mice has conventionally been diagnosed when motor deficits reflect advanced neurodegeneration. Now, the identification of earlier dysfunction helps direct the study of mechanisms of neurotoxicity and therapies to earlier stages of disease, when rescue is still possible. The key finding is that with reversal of neurotoxic mechanisms at this synaptic stage of prion disease, neurons are saved from degeneration. Many questions still need addressing for both prion and other neurodegenerative disorders. The mechanisms by which putative toxic PrP oligomers or intermediates (and indeed the nature or identity of these) cause synaptic dysfunction are still unknown. There is evidence of PrP interaction with NMDA (N-methyl-Daspartate) receptors [36] , and for PrP-mediating toxicity of Aβ oligomers at the level of LTP [37] , but clearly there are multiple effects at many levels of the functioning synaptic unit and in the integration of the activity of multiple synapses. Moreover, how synaptic dysfunction ultimately leads to neuronal cell death is not known, nor, critically, do we know what is the threshold of malfunction up to which sick synapses can be rescued. The extent to which spine and synaptic regeneration play a part in recovery is also not known and needs exploring. It may be that individual strategies are needed for individual diseases, or that there are common pathways that will allow a more global intervention, independent of specific pathology. Clearly, the search for both generic and specific mechanisms and solutions is critically important. A key advance, however, is the focus on finding new early clinical readouts of neurodegenerative disease, both in mice and ultimately in humans. Early detection is essential for any intervention and the possibility of preclinical testing of therapeutic strategies through cognitive endpoints in these disorders is well worth pursuing.
